The role of sphingosine 1-phosphate receptor 2 in bile-acid–induced cholangiocyte proliferation and cholestasis-induced liver injury in mice

Hepatology

Volumn 65, Issue 6, 2017, Pages 2005-2018

  Wang, Yongqing ^a,b   Aoki, Hiroaki ^c   Yang, Jing ^b,d   Peng, Kesong ^b,e   Liu, Runping ^b   Li, Xiaojiaoyang ^b,d   Qiang, Xiaoyan ^b,d   Sun, Lixin ^b,d   Gurley, Emily C ^b   Lai, Guanhua ^c   Zhang, Luyong ^d   Liang, Guang ^e   Nagahashi, Masayuki ^f   Takabe, Kazuaki ^b,g   Pandak, William M ^b   Hylemon, Phillip B ^b   Zhou, Huiping ^b,e  

^a NANJING MEDICAL UNIVERSITY   (China)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHINA PHARMACEUTICAL UNIVERSITY   (China)

^e WENZHOU MEDICAL UNIVERSITY   (China)

^f NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2,6 DICHLORO 4 PYRIDINYL) 1 (1,3 DIMETHYL 4 ISOPROPYL 1H PYRAZOLO[3,4 B]PYRIDIN 6 YL)SEMICARBAZIDE; BILE ACID CONJUGATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SHORT HAIRPIN RNA; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 2; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; BILE ACID; LYSOPHOSPHOLIPID; MAPK1 PROTEIN, MOUSE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE-1-PHOSPHATE RECEPTOR-2, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILE DUCT LIGATION; CELL MIGRATION; CELL PROLIFERATION; CHOLANGIOCYTE; CHOLESTASIS; CONTROLLED STUDY; FEMALE; KNOCKOUT MOUSE; LIVER FIBROSIS; LIVER INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; BILE DUCT; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CBA MOUSE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; INJURIES; LIGATION; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; ROLE PLAYING; SCLEROSING CHOLANGITIS; SIGNAL TRANSDUCTION; SURGERY;

ANALYSIS OF VARIANCE; ANIMALS; BILE ACIDS AND SALTS; BILE DUCT NEOPLASMS; BILE DUCTS; CELL PROLIFERATION; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; CHOLESTASIS; DISEASE MODELS, ANIMAL; LIGATION; LIVER; LIVER CIRRHOSIS; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED CBA; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; RANDOM ALLOCATION; RECEPTORS, LYSOSPHINGOLIPID; ROLE; SIGNAL TRANSDUCTION; SPHINGOSINE; UP-REGULATION;

EID: 85019004624     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29076     Document Type: Article

References (49)

1. Hirschfield GM, Heathcote EJ. Cholestasis and cholestatic syndromes. Curr Opin Gastroenterol 2009;25:175-179.
2. O'Leary JG, Pratt DS. Cholestasis and cholestatic syndromes. Curr Opin Gastroenterol 2007;23:232-236.
3. Glaser SS, Gaudio E, Miller T, Alvaro D, Alpini G. Cholangiocyte proliferation and liver fibrosis. Expert Rev Mol Med 2009;11:e7.
4. Hall C, Sato K, Wu N, Zhou T, Kyritsi T, Meng F, et al. Regulators of cholangiocyte proliferation. Gene Expr 2017;17:155-171.
5. Glaser S, Onori P, Gaudio E, Ueno Y, Pannarale L, Franchitto A, et al. Taurocholic acid prevents biliary damage induced by hepatic artery ligation in cholestatic rats. Dig Liver Dis 2010;42:709-717.
6. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J Lipid Res 2009;50:1509-1520.
7. Zhou H, Hylemon PB. Bile acids are nutrient signaling hormones. Steroids 2014;86:62-68.
8. Nagahashi M, Yuza K, Hirose Y, Nakajima M, Ramanathan R, Hait NC, et al. The roles of bile acids and sphingosine-1-phosphate signaling in the hepato-biliary diseases. J Lipid Res 2016;57:1636-1643.
9. Takabe K, Paugh SW, Milstien S, Spiegel S. “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008;60:181-195.
10. Takabe K, Spiegel S. Export of sphingosine-1-phosphate and cancer progression. J Lipid Res 2014;55:1839-1846.
11. Malik FA, Meissner A, Semenkov I, Molinski S, Pasyk S, Ahmadi S, et al. Sphingosine-1-phosphate is a novel regulator of cystic fibrosis transmembrane conductance regulator (CFTR) Activity. PLoS One 2015;10:e0130313.
12. Zhao CG, Qin J, He XJ, Guan YC, Jia Y, Lei W. Sphingosine-1-phosphate is a possible fibrogenic factor in gluteal muscle fibrosis. Physiol Res 2013;62:691-699.
13. Li C, Zheng S, You H, Liu X, Lin M, Yang L, Li L. Sphingosine 1-phosphate (S1P)/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility. J Hepatol 2011;54:1205-1213.
14. Ikeda H, Watanabe N, Ishii I, Shimosawa T, Kume Y, Tomiya T, et al. Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2. J Lipid Res 2009;50:556-564.
15. Li C, Jiang X, Yang L, Liu X, Yue S, Li L. Involvement of sphingosine 1-phosphate (SIP)/S1P3 signaling in cholestasis-induced liver fibrosis. Am J Pathol 2009;175:1464-1472.
16. Yang L, Han Z, Tian L, Mai P, Zhang Y, Wang L, Li L. Sphingosine 1-phosphate receptor 2 and 3 mediate bone marrow-derived monocyte/macrophage motility in cholestatic liver injury in mice. Sci Rep 2015;5:13423.
17. Kageyama Y, Ikeda H, Watanabe N, Nagamine M, Kusumoto Y, Yashiro M, et al. Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents. Hepatology 2012;56:1427-1438.
18. Studer E, Zhou X, Zhao R, Wang Y, Takabe K, Nagahashi M, et al. Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology 2012;55:267-276.
19. Nagahashi M, Takabe K, Liu R, Peng K, Wang X, Wang Y, et al. Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. Hepatology 2015;61:1216-1226.
20. Liu R, Li X, Qiang X, Luo L, Hylemon PB, Jiang Z, et al. Taurocholate induces cyclooxygenase-2 expression via the sphingosine 1-phosphate receptor 2 in a human cholangiocarcinoma cell line. J Biol Chem 2015;290:30988-31002.
21. Liu R, Zhao R, Zhou X, Liang X, Campbell DJ, Zhang X, et al. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. Hepatology 2014;60:908-918.
22. Glaser SS, Gaudio E, Rao A, Pierce LM, Onori P, Franchitto A, et al. Morphological and functional heterogeneity of the mouse intrahepatic biliary epithelium. Lab Invest 2009;89:456-469.
23. Aoki H, Aoki M, Yang J, Katsuta E, Mukhopadhyay P, Ramanathan R, et al. Murine model of long-term obstructive jaundice. J Surg Res 2016;206:118-125.
24. Marzioni M, Ueno Y, Glaser S, Francis H, Benedetti A, Alvaro D, et al. Cytoprotective effects of taurocholic acid feeding on the biliary tree after adrenergic denervation of the liver. Liver Int 2007;27:558-568.
25. Marucci L, Alpini G, Glaser SS, Alvaro D, Benedetti A, Francis H, et al. Taurocholate feeding prevents CCl4-induced damage of large cholangiocytes through PI3-kinase-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 2003;284:G290-G301.
26. Marzioni M, LeSage GD, Glaser S, Patel T, Marienfeld C, Ueno Y, et al. Taurocholate prevents the loss of intrahepatic bile ducts due to vagotomy in bile duct-ligated rats. Am J Physiol Gastrointest Liver Physiol 2003;284:G837-G852.
27. Zhang Y, Hong JY, Rockwell CE, Copple BL, Jaeschke H, Klaassen CD. Effect of bile duct ligation on bile acid composition in mouse serum and liver. Liver Int 2012;32:58-69.
28. Luo L, Schomaker S, Houle C, Aubrecht J, Colangelo JL. Evaluation of serum bile acid profiles as biomarkers of liver injury in rodents. Toxicol Sci 2014;137:12-25.
29. Yamazaki M, Miyake M, Sato H, Masutomi N, Tsutsui N, Adam KP, et al. Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats. Toxicol Appl Pharmacol 2013;268:79-89.
30. Lin Y, Si D, Zhang Z, Liu C. An integrated metabonomic method for profiling of metabolic changes in carbon tetrachloride induced rat urine. Toxicology 2009;256:191-200.
31. Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology 2017;65:350-362.
32. Zhang Y, Pan Y, Lin C, Zheng Y, Sun H, Zhang H, et al. Bile acids evoke placental inflammation by activating Gpbar1/NF-kappaB pathway in intrahepatic cholestasis of pregnancy. J Mol Cell Biol 2016;8:530-541.
33. Zhu C, Fuchs CD, Halilbasic E, Trauner M. Bile acids in regulation of inflammation and immunity: friend or foe? Clin Exp Rheumatol 2016;34:25-31.
34. Masyuk TV, Masyuk AI, LaRusso NF. TGR5 in the cholangiociliopathies. Dig Dis 2015;33:420-425.
35. Keitel V, Reich M, Haussinger D. TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis? Clin Rev Allergy Immunol 2015;48:218-225.
36. Pean N, Doignon I, Tordjmann T. Bile acids and liver carcinogenesis: TGR5 as a novel piece in the puzzle? Clin Res Hepatol Gastroenterol 2013;37:226-229.
37. Reich M, Deutschmann K, Sommerfeld A, Klindt C, Kluge S, Kubitz R, et al. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. Gut 2016;65:487-501.
38. Yang Z, Xiong F, Wang Y, Gong W, Huang J, Chen C, et al. TGR5 activation suppressed S1P/S1P2 signaling and resisted high glucose-induced fibrosis in glomerular mesangial cells. Pharmacol Res 2016;111:226-236.
39. Rao YP, Studer EJ, Stravitz RT, Gupta S, Qiao L, Dent P, Hylemon PB. Activation of the Raf-1/MEK/ERK cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes. Hepatology 2002;35:307-314.
40. Kosters A, Karpen SJ. The role of inflammation in cholestasis: clinical and basic aspects. Semin Liver Dis 2010;30:186-194.
41. Yaghobian D, Don AS, Yaghobian S, Chen X, Pollock CA, Saad S. Increased sphingosine 1-phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy. Clin Exp Pharmacol Physiol 2016;43:56-66.
42. Liu X, Hong Q, Wang Z, Yu Y, Zou X, Xu L. Transforming growth factor-beta-sphingosine kinase 1/S1P signaling upregulates microRNA-21 to promote fibrosis in renal tubular epithelial cells. Exp Biol Med (Maywood) 2016;241:265-272.
43. Huang LS, Natarajan V. Sphingolipids in pulmonary fibrosis. Adv Biol Regul 2015;57:55-63.
44. Yang L, Yue S, Yang L, Liu X, Han Z, Zhang Y, Li L. Sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis is involved in liver fibrosis-associated angiogenesis. J Hepatol 2013;59:114-123.
45. Shiohira S, Yoshida T, Sugiura H, Nishida M, Nitta K, Tsuchiya K. Sphingosine-1-phosphate acts as a key molecule in the direct mediation of renal fibrosis. Physiol Rep 2013;1:e00172.
46. Li C, Kong Y, Wang H, Wang S, Yu H, Liu X, et al. Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis. J Hepatol 2009;50:1174-1183.
47. O'Brien KM, Allen KM, Rockwell CE, Towery K, Luyendyk JP, Copple BL. IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis. Am J Pathol 2013;183:1498-1507.
48. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009;325:1254-1257.
49. Hait NC, Bellamy A, Milstien S, Kordula T, Spiegel S. Sphingosine kinase type 2 activation by ERK-mediated phosphorylation. J Biol Chem 2007;282:12058-12065.